Table I.
Clinicopathological features of primary BC patient and control tissues (surrounding normal tissues and normal bladder mucosae).
| BC (140) | ||||
|---|---|---|---|---|
| Variables | NMIBC | MIBC | Control | P-value |
| No. | 97 | 43 | 97 | |
| Mean age ± SD | 63.45±13.79 | 67.60±9.84 | 61.98±14.32 | 0.083a |
| Sex (%) | 0.975a | |||
| Male | 80 (82.5%) | 36 (83.7%) | 81 (83.5%) | |
| Female | 17 (17.5%) | 7 (16.3%) | 16 (16.5%) | |
| Operation (%) | <0.001b | |||
| TUR-BT | 97 (100.0%) | 17 (39.5%) | ||
| Radical cystectomy | 0 | 26 (60.5%) | ||
| Tumor size (%) | 0.003b | |||
| ≤1 cm | 16 (16.5%) | 2 (4.7%) | ||
| 2–3 cm | 37 (38.1%) | 11 (25.6%) | ||
| >3 cm | 37 (38.1%) | 28 (65.1%) | ||
| Multiplicity (%) | 0.108b | |||
| Single | 52 (53.6%) | 30 (69.8%) | ||
| 2–7 | 28 (28.9%) | 7 (16.3%) | ||
| >7 | 11 (11.3%) | 4 (9.3%) | ||
| Grade, 2004 WHO grading system (%) | <0.001b | |||
| Low | 72 (74.2%) | 8 (18.6%) | ||
| High | 25 (25.8%) | 35 (81.4%) | ||
| Stage (%) | <0.001b | |||
| TaN0M0 | 26 (26.8%) | |||
| T1N0M0 | 71 (73.2%) | |||
| T2N0M0 | 13 (30.2%) | |||
| T3N0M0 | 6 (14.0%) | |||
| T≥4 or N≥1 or M1 | 24 (55.8%) | |||
| Chemotherapy (%) | <0.001b | |||
| No | 97 (100.0%) | 23 (53.5%) | ||
| Yes | 0 | 20 (46.5%) | ||
| BCG therapy (%) | <0.001b | |||
| No | 56 (57.7%) | 38 (88.4%) | ||
| Yes | 40 (41.2%) | 5 (11.6%) | ||
| Recurrence, no. of patients (%) | ||||
| No | 59 (60.8%) | – | ||
| Yes | 38 (39.2%) | – | ||
| Progression, no. of patients (%) | 0.126b | |||
| No | 79 (81.4%) | 30 (69.8%) | ||
| Yes | 18 (18.6%) | 13 (30.2%) | ||
| Survival, no. of patients (%) | 0.009b | |||
| Alive | 64 (66.0%) | 21 (48.8%) | ||
| Non-cancer-specific death | 18 (18.6%) | 3 (7.0%) | ||
| Cancer-specific death | 15 (15.5%) | 19 (44.2%) | ||
| Mean follow-up, months (range) | 72.95 (3.20–172.20) | 36.18 (3.00–141.40) | ||
a
P-value obtained using Kruskal-Wallis H test (BC compared with control).
b
P-value obtained using the Mann-Whitney U test (NMIBC compared with MIBC). BC, bladder cancer; BCG, Bacillus Calmette-Guerin; NMIBC, non-muscle invasive bladder cancer; MIBC, muscle invasive bladder cancer; SD, standard deviation.